Evaluation of the clinical significance of the ALDH1A1-ZBTB7B axis in NSCLC patients treated with PD-1 mAb revealed that high expression indicated poorer therapeutic outcomes in NSCLC patients responding to PD-1 mAb therapy. This evidence concerns the gene ZBTB7B and non-small cell lung carcinoma.